{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:54:38Z","timestamp":1794275678342,"version":"4.9.0"},"reference-count":190,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T00:00:00Z","timestamp":1699833600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","surveyophthalmol.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Survey of Ophthalmology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.survophthal.2023.10.008","type":"journal-article","created":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T15:09:42Z","timestamp":1698332982000},"page":"265-278","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Management of vernal keratoconjunctivitis: Navigating a changing treatment landscape"],"prefix":"10.1016","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6896-8507","authenticated-orcid":false,"given":"Asim","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Bielory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Dotchin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Hamel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi Ning J.","family":"Strube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Euna B.","family":"Koo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.survophthal.2023.10.008_bib1","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2147\/OPTH.S129552","article-title":"Vernal keratoconjunctivitis","volume":"12","author":"Addis","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib2","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s40268-019-00288-x","article-title":"A clinician\u2019s guide to the recognition and management of dupilumab-associated conjunctivitis","volume":"19","author":"Agnihotri","year":"2019","journal-title":"Drugs R&D"},{"key":"10.1016\/j.survophthal.2023.10.008_bib3","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s13346-016-0339-2","article-title":"A comprehensive insight on ocular pharmacokinetics","volume":"6","author":"Agrahari","year":"2016","journal-title":"Drug Deliv Transl Res"},{"issue":"Pt 2","key":"10.1016\/j.survophthal.2023.10.008_bib4","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/eye.1998.67","article-title":"Effects of lodoxamide, disodium cromoglycate and fluorometholone on tear leukotriene levels in vernal keratoconjunctivitis","volume":"12","author":"Akman","year":"1998","journal-title":"Eye"},{"key":"10.1016\/j.survophthal.2023.10.008_bib5","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1076\/ocii.6.3.179.4042","article-title":"Effect of lodoxamide on tear leukotriene levels in giant papillary conjunctivitis associated with ocular prosthesis","volume":"6","author":"Akman","year":"1998","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.survophthal.2023.10.008_bib6","doi-asserted-by":"crossref","first-page":"135","DOI":"10.4103\/0974-9233.164616","article-title":"Tacrolimus ointment for treatment of vernal keratoconjunctivitis","volume":"23","author":"Al-Amri","year":"2016","journal-title":"Middle East Afr J Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib7","doi-asserted-by":"crossref","first-page":"145","DOI":"10.4103\/ojo.OJO_232_2014","article-title":"Long-term use of 0.003% tacrolimus suspension for treatment of vernal keratoconjunctivitis","volume":"10","author":"Al-Amri","year":"2017","journal-title":"Oman J Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0215528","article-title":"Prevalence of vernal keratoconjunctivitis and its associated factors among children in Gambella town, southwest Ethiopia, June 2018","volume":"14","author":"Alemayehu","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.survophthal.2023.10.008_bib9","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.2147\/OPTH.S32936","article-title":"Steroid-induced ocular hypertension in Asian children with severe vernal keratoconjunctivitis","volume":"6","author":"Ang","year":"2012","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib10","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1111\/pai.13520","article-title":"Health-related quality of life in children at the diagnosis of Vernal Keratoconjunctivitis","volume":"32","author":"Artesani","year":"2021","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib11","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/S0161-6420(00)00089-0","article-title":"Mechanisms and comparison of anti-allergic efficacy of topical lodoxamide and cromolyn sodium treatment in vernal keratoconjunctivitis","volume":"107","author":"Avunduk","year":"2000","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2023.10.008_bib12","article-title":"Epidemiology of vernal keratoconjunctivitis in the United States: a claims data analysis","volume":"61","author":"Babineaux","year":"2020","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"10.1016\/j.survophthal.2023.10.008_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jdin.2021.03.009","article-title":"Encounters and medication use for ocular surface disorders among patients treated with dupilumab: a cohort study","volume":"4","author":"Barbieri","year":"2021","journal-title":"JAAD Int"},{"key":"10.1016\/j.survophthal.2023.10.008_bib14","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.3928\/01913913-20210708-02","article-title":"Vernal keratoconjunctivitis: beyond the classic treatment","volume":"58","author":"Bernales","year":"2021","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"10.1016\/j.survophthal.2023.10.008_bib15","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/ACI.0b013e32833dfa28","article-title":"Treatment of seasonal allergic conjunctivitis with ophthalmic corticosteroids: in search of the perfect ocular corticosteroids in the treatment of allergic conjunctivitis","volume":"10","author":"Bielory","year":"2010","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib16","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1517\/14656566.2013.849242","article-title":"Bepotastine besilate for the treatment of pruritus","volume":"14","author":"Bielory","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.survophthal.2023.10.008_bib17","doi-asserted-by":"crossref","first-page":"408","DOI":"10.2500\/aap.2013.34.3695","article-title":"An algorithm for the management of allergic conjunctivitis","volume":"34","author":"Bielory","year":"2013","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.survophthal.2023.10.008_bib18","doi-asserted-by":"crossref","DOI":"10.1007\/s11882-019-0844-8","article-title":"Emerging therapeutics for ocular surface disease","volume":"19","author":"Bielory","year":"2019","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.survophthal.2023.10.008_bib19","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.anai.2019.11.014","article-title":"ICON: diagnosis and management of allergic conjunctivitis","volume":"124","author":"Bielory","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib20","first-page":"1374","article-title":"Treating severe pediatric keratoconjunctivitis with topical cyclosporine A","volume":"239","author":"Biermann","year":"2021","journal-title":"Klin Monbl Augenheilkd"},{"key":"10.1016\/j.survophthal.2023.10.008_bib21","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1001\/archophthalmol.2011.82","article-title":"Elevation of intraocular pressure in patients with uveitis treated with topical difluprednate","volume":"129","author":"Birnbaum","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib22","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/S0161-6420(91)32069-4","article-title":"Topical cyclosporine in vernal keratoconjunctivitis","volume":"98","author":"Bleik","year":"1991","journal-title":"Ophthalmology"},{"issue":"Pt 6","key":"10.1016\/j.survophthal.2023.10.008_bib23","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/eye.1992.139","article-title":"Effectiveness of nedocromil sodium 2% eyedrops on clinical symptoms and tear fluid cytology of patients with vernal conjunctivitis","volume":"6","author":"Bonini","year":"1992","journal-title":"Eye"},{"key":"10.1016\/j.survophthal.2023.10.008_bib24","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1398-9995.1997.tb04810.x","article-title":"The eosinophil and the eye","volume":"52","author":"Bonini","year":"1997","journal-title":"Allergy"},{"key":"10.1016\/j.survophthal.2023.10.008_bib25","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0161-6420(97)30223-1","article-title":"Efficacy of lodoxamide eye drops on mast cells and eosinophils after allergen challenge in allergic conjunctivitis","volume":"104","author":"Bonini","year":"1997","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2023.10.008_bib26","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0161-6420(00)00092-0","article-title":"Vernal keratoconjunctivitis revisited: a case series of 195 patients with long-term followup","volume":"107","author":"Bonini","year":"2000","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2023.10.008_bib27","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/sj.eye.6700675","article-title":"Vernal keratoconjunctivitis","volume":"18","author":"Bonini","year":"2004","journal-title":"Eye"},{"key":"10.1016\/j.survophthal.2023.10.008_bib28","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/ACI.0b013e3282efb726","article-title":"Clinical grading of vernal keratoconjunctivitis","volume":"7","author":"Bonini","year":"2007","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib29","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1136\/bjo.2007.117812","article-title":"Prevalence of vernal keratoconjunctivitis: a rare disease?","volume":"92","author":"Bremond-Gignac","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib30","unstructured":"Bremond-Gignac D, Aragona P, Doan S, et al. Safety and Tolerability of Topical Cyclosporine A Cationic Emulsion in Patients with Active Severe Vernal Keratoconjunctivitis (VKC) in Pediatric Patients: Pooled Results of the NOVATIVE and VEKTIS Trials (Poster 6710-B0165): Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), Vancouver, BC, Canada; 2019."},{"key":"10.1016\/j.survophthal.2023.10.008_bib31","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ajo.2019.11.020","article-title":"Twelve-month results of cyclosporine a cationic emulsion in a randomized study in patients with pediatric vernal keratoconjunctivitis","volume":"212","author":"Bremond-Gignac","year":"2020","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib32","article-title":"Vernal keratoconjunctivitis: state of art and update on treatment","volume":"92","author":"Brindisi","year":"2021","journal-title":"Acta Biomed"},{"key":"10.1016\/j.survophthal.2023.10.008_bib33","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/j.1476-5381.1990.tb13009.x","article-title":"Inhibition of neutrophil and eosinophil induced chemotaxis by nedocromil sodium and sodium cromoglycate","volume":"99","author":"Bruijnzeel","year":"1990","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib34","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007685.pub2","article-title":"Sublingual immunotherapy for treating allergic conjunctivitis","author":"Calderon","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.survophthal.2023.10.008_bib35","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1097\/ICO.0000000000002751","article-title":"Long-term safety and efficacy of tacrolimus 0.1% in severe pediatric vernal keratoconjunctivitis","volume":"40","author":"Caputo","year":"2021","journal-title":"Cornea"},{"key":"10.1016\/j.survophthal.2023.10.008_bib36","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1097\/ICO.0000000000000918","article-title":"Tacrolimus in corticosteroid-refractory vernal keratoconjunctivitis","volume":"35","author":"Chatterjee","year":"2016","journal-title":"Cornea"},{"key":"10.1016\/j.survophthal.2023.10.008_bib37","doi-asserted-by":"crossref","first-page":"AB216","DOI":"10.1016\/j.jaci.2021.12.708","article-title":"Ocular allergic surface disease symptoms associated with atopic keratoconjunctivitis (AKC) alleviated with dupilumab","volume":"149","author":"Chen","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib38","article-title":"Combination of 0.05% azelastine and 0.1% tacrolimus eye drops in children with vernal keratoconjunctivitis: a prospective study","volume":"8","author":"Chen","year":"2021","journal-title":"Front Med"},{"key":"10.1016\/j.survophthal.2023.10.008_bib39","article-title":"Combination therapy of 0.1% fluorometholone and 0.05% azelastine in eyes with severe allergic conjunctival diseases: a randomized controlled trial","volume":"11","author":"Chen","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.survophthal.2023.10.008_bib40","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.2147\/OPTH.S63790","article-title":"Update and clinical utility of alcaftadine ophthalmic solution 0.25% in the treatment of allergic conjunctivitis","volume":"9","author":"Chigbu","year":"2015","journal-title":"Clin Ophthalmol"},{"issue":"7","key":"10.1016\/j.survophthal.2023.10.008_bib41","doi-asserted-by":"crossref","first-page":"658","DOI":"10.3390\/ph14070658","article-title":"Immunopharmacology in vernal keratoconjunctivitis: current and future perspectives","volume":"14","author":"Chigbu","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.survophthal.2023.10.008_bib42","first-page":"410","article-title":"Efficacy of topical 0.05% cyclosporine treatment in children with severe vernal keratoconjunctivitis","volume":"56","author":"\u00c7oban-Karata\u015f","year":"2014","journal-title":"Turk J Pediatr"},{"key":"10.1016\/j.survophthal.2023.10.008_bib43","doi-asserted-by":"crossref","first-page":"19","DOI":"10.15353\/cjo.77.486","article-title":"Vernal keratoconjunctivitis and its management challenges","volume":"77","author":"Collins","year":"2015","journal-title":"Can J Optom"},{"key":"10.1016\/j.survophthal.2023.10.008_bib44","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1081-1206(10)62926-2","article-title":"Olopatadine inhibits anti-immunoglobulin E-stimulated conjunctival mast cell upregulation of ICAM-1 expression on conjunctival epithelial cells","volume":"87","author":"Cook","year":"2001","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib45","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1089\/jop.2005.21.400","article-title":"Efficiency of olopatadine hydrochloride 0.1% in the treatment of vernal keratoconjunctivitis and goblet cell density","volume":"21","author":"Corum","year":"2005","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.survophthal.2023.10.008_bib46","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s00417-002-0612-6","article-title":"Preservative-free diclofenac sodium 0.1% for vernal keratoconjunctivitis","volume":"241","author":"D'Angelo","year":"2003","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib47","doi-asserted-by":"crossref","first-page":"186","DOI":"10.5935\/0004-2749.20170045","article-title":"Supratarsal injection of triamcinolone for severe vernal keratoconjunctivitis in children","volume":"80","author":"Da Costa","year":"2017","journal-title":"Arq Bras Oftalmol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib48","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/s40123-023-00665-5","article-title":"Novel insights in the management of vernal keratoconjunctivitis (VKC): European expert consensus using a modified nominal group technique","volume":"12","author":"Dahlmann-Noor","year":"2023","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.survophthal.2023.10.008_bib49","first-page":"239","article-title":"Safety and efficacy of lodoxamide in vernal keratoconjunctivitis","volume":"61","author":"Das","year":"2011","journal-title":"J Pak Med Assoc"},{"key":"10.1016\/j.survophthal.2023.10.008_bib50","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/ICO.0b013e31825e83f4","article-title":"Distribution of cyclosporine A in ocular tissues after topical administration of cyclosporine A cationic emulsions to pigmented rabbits","volume":"32","author":"Daull","year":"2013","journal-title":"Cornea"},{"key":"10.1016\/j.survophthal.2023.10.008_bib51","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/jphp.12075","article-title":"Benefits of cetalkonium chloride cationic oil-in-water nanoemulsions for topical ophthalmic drug delivery","volume":"66","author":"Daull","year":"2014","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib52","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jaapos.2012.12.153","article-title":"Severe vernal keratoconjunctivitis successfully treated with subcutaneous omalizumab","volume":"17","author":"de Klerk","year":"2013","journal-title":"J AAPOS"},{"key":"10.1016\/j.survophthal.2023.10.008_bib53","doi-asserted-by":"crossref","first-page":"711","DOI":"10.4269\/ajtmh.2011.11-0291","article-title":"Vernal keratoconjunctivitis in school children in Rwanda and its association with socio-economic status: a population-based survey","volume":"85","author":"De Smedt","year":"2011","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.survophthal.2023.10.008_bib54","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1136\/bjophthalmol-2011-300415","article-title":"Topical ciclosporin in the treatment of vernal keratoconjunctivitis in Rwanda, Central Africa: a prospective, randomised, double-masked, controlled clinical trial","volume":"96","author":"De Smedt","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib55","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/bjophthalmol-2011-301376","article-title":"Vernal keratoconjunctivitis: an update","volume":"97","author":"De Smedt","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib56","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1016\/j.ophtha.2012.03.041","article-title":"Vernal keratoconjunctivitis in school children in Rwanda: clinical presentation, impact on school attendance, and access to medical care","volume":"119","author":"De Smedt","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2023.10.008_bib57","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jtos.2019.07.004","article-title":"Adult vernal keratoconjunctivitis: clinical and biochemical profile of a rare disease","volume":"17","author":"Di Zazzo","year":"2019","journal-title":"Ocul Surf"},{"key":"10.1016\/j.survophthal.2023.10.008_bib58","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40123-016-0074-2","article-title":"Omalizumab in severe refractory vernal keratoconjunctivitis in children: case series and review of the literature","volume":"6","author":"Doan","year":"2017","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.survophthal.2023.10.008_bib59","doi-asserted-by":"crossref","DOI":"10.1186\/s13223-020-0403-9","article-title":"A contemporary look at allergic conjunctivitis","volume":"16","author":"Dupuis","year":"2020","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib60","first-page":"78","article-title":"In brief: OTC alcaftadine (Lastacaft Once Daily Relief) for allergic conjunctivitis","volume":"64","year":"2022","journal-title":"Med Lett Drugs Ther"},{"key":"10.1016\/j.survophthal.2023.10.008_bib61","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s12016-015-8490-y","article-title":"Off-label uses of omalizumab","volume":"50","author":"El-Qutob","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib62","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/bjo.78.5.365","article-title":"A double blind placebo controlled group comparative study of ophthalmic sodium cromoglycate and nedocromil sodium in the treatment of vernal keratoconjunctivitis","volume":"78","author":"el Hennawi","year":"1994","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib63","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/all.13334","article-title":"Clinical implications of mast cell involvement in allergic conjunctivitis","volume":"73","author":"Elieh Ali Komi","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.survophthal.2023.10.008_bib64","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/pai.13035","article-title":"Diagnosing and managing allergic conjunctivitis in childhood: the allergist's perspective","volume":"30","author":"Fauquert","year":"2019","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib65","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0161-6420(88)33201-X","article-title":"Evaluation of topical cromolyn sodium in the treatment of vernal keratoconjunctivitis","volume":"95","author":"Foster","year":"1988","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2023.10.008_bib66","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.jaip.2019.10.011","article-title":"Amelioration of conjunctival giant papillae by dupilumab in patients with atopic keratoconjunctivitis","volume":"8","author":"Fukuda","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.survophthal.2023.10.008_bib67","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1136\/bjophthalmol-2013-304453","article-title":"Therapeutic effects of 0.1% tacrolimus eye drops for refractory allergic ocular diseases with proliferative lesion or corneal involvement","volume":"98","author":"Fukushima","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib68","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1159\/000508031","article-title":"Vernal keratoconjunctivitis: a case of anti-IgE treatment with short-lasting remission","volume":"11","author":"Gatta","year":"2020","journal-title":"Case Rep Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib69","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3928\/01913913-20210319-01","article-title":"Understanding the journey of patients with vernal keratoconjunctivitis: a qualitative study of the impact on children and families","volume":"58","author":"Ghauri","year":"2021","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"10.1016\/j.survophthal.2023.10.008_bib70","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1177\/11206721211022153","article-title":"Vernal keratoconjunctivitis: an update","volume":"31","author":"Ghiglioni","year":"2021","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib71","doi-asserted-by":"crossref","first-page":"220","DOI":"10.4103\/0301-4738.95878","article-title":"Oral cyclosporine therapy for refractory severe vernal keratoconjunctivitis","volume":"60","author":"Gokhale","year":"2012","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib72","doi-asserted-by":"crossref","first-page":"145","DOI":"10.4103\/0301-4738.179727","article-title":"Systematic approach to managing vernal keratoconjunctivitis in clinical practice: severity grading system and a treatment algorithm","volume":"64","author":"Gokhale","year":"2016","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib73","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.aller.2017.12.002","article-title":"Quality of life and clinical characterization of patients with vernal keratoconjunctivitis in a pediatric population in Colombia","volume":"46","author":"G\u00f3mez-Henao","year":"2018","journal-title":"Allergol Immunopathol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib74","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S0161-6420(00)00538-8","article-title":"Keratitis, ulceration, and perforation associated with topical nonsteroidal anti-inflammatory drugs","volume":"108","author":"Guidera","year":"2001","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2023.10.008_bib75","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/eye.2001.10","article-title":"Topical cyclosporin A in the management of vernal keratoconjunctivitis","volume":"15","author":"Gupta","year":"2001","journal-title":"Eye"},{"key":"10.1016\/j.survophthal.2023.10.008_bib76","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/s41433-021-01484-3","article-title":"Efficacy of montelukast in preventing seasonal recurrence of vernal keratoconjunctivitis in children","volume":"36","author":"Hardas","year":"2022","journal-title":"Eye"},{"key":"10.1016\/j.survophthal.2023.10.008_bib77","doi-asserted-by":"crossref","DOI":"10.1186\/s12886-016-0345-7","article-title":"Prevalence and associated factors of vernal keratoconjunctivitis among children in Gondar city, Northwest Ethiopia","volume":"16","author":"Hayilu","year":"2016","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib78","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1001\/jamaophthalmol.2015.5679","article-title":"Omalizumab treatment of vernal keratoconjunctivitis","volume":"134","author":"Heffler","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib79","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00417-021-05356-0","article-title":"A comparative study between ciclosporine A eye drop (2%) and tacrolimus eye ointment (0.03%) in management of children with refractory vernal keratoconjunctivitis","volume":"260","author":"Heikal","year":"2022","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib80","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/ICO.0000000000002692","article-title":"Evaluation of clinical efficacy and safety of prolonged treatment of vernal and atopic keratoconjunctivitis using topical tacrolimus","volume":"41","author":"Hirota","year":"2022","journal-title":"Cornea"},{"key":"10.1016\/j.survophthal.2023.10.008_bib81","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0002-9394(14)70271-5","article-title":"Supratarsal injection of corticosteroid in the treatment of refractory vernal keratoconjunctivitis","volume":"121","author":"Holsclaw","year":"1996","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib82","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/01.ICL.0000092071.82938.46","article-title":"Long-term safety of loteprednol etabonate 0.2% in the treatment of seasonal and perennial allergic conjunctivitis","volume":"30","author":"Ilyas","year":"2004","journal-title":"Eye Contact Lens"},{"key":"10.1016\/j.survophthal.2023.10.008_bib83","doi-asserted-by":"crossref","first-page":"455","DOI":"10.17219\/acem\/37145","article-title":"Topical cyclosporine a 0.05% eyedrops in the treatment of vernal keratoconjunctivitis - randomized placebo-controlled trial","volume":"23","author":"Keklikci","year":"2014","journal-title":"Adv Clin Exp Med"},{"key":"10.1016\/j.survophthal.2023.10.008_bib84","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/eye.2011.75","article-title":"Topical 0.005% tacrolimus eye drop for refractory vernal keratoconjunctivitis","volume":"25","author":"Kheirkhah","year":"2011","journal-title":"Eye"},{"key":"10.1016\/j.survophthal.2023.10.008_bib85","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.ophtha.2012.12.022","article-title":"A randomized, multicenter phase 3 study comparing 2% rebamipide (OPC-12759) with 0.1% sodium hyaluronate in the treatment of dry eye","volume":"120","author":"Kinoshita","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2023.10.008_bib86","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1398-9995.1995.tb04252.x","article-title":"Clinical experience with Tilavist: an overview of efficacy and safety","volume":"50","author":"Kjellman","year":"1995","journal-title":"Allergy"},{"key":"10.1016\/j.survophthal.2023.10.008_bib87","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.preteyeres.2005.09.002","article-title":"Role of structural cells of the cornea and conjunctiva in the pathogenesis of vernal keratoconjunctivitis","volume":"25","author":"Kumagai","year":"2006","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.survophthal.2023.10.008_bib88","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11882-010-0101-7","article-title":"Modern approach to managing vernal keratoconjunctivitis","volume":"10","author":"Kumar","year":"2010","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.survophthal.2023.10.008_bib89","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3126\/nepjoph.v9i2.19257","article-title":"Tacrolimus versus cyclosporine- comparative evaluation as first line drug in vernal keratoconjuctivitis","volume":"9","author":"Kumari","year":"2017","journal-title":"Nepal J Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib90","first-page":"177","article-title":"A double-masked comparison of 0.1% tacrolimus ointment and 2% cyclosporine eye drops in the treatment of vernal keratoconjunctivitis in children","volume":"30","author":"Labcharoenwongs","year":"2012","journal-title":"Asian Pac J Allergy Immunol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib91","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/604204","article-title":"Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb","volume":"2012","author":"Lallemand","year":"2012","journal-title":"J Drug Deliv"},{"key":"10.1016\/j.survophthal.2023.10.008_bib92","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1001\/archopht.121.5.615","article-title":"Montelukast, a leukotriene receptor antagonist, in vernal keratoconjunctivitis associated with asthma","volume":"121","author":"Lambiase","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib93","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jaci.2011.07.004","article-title":"Topical cyclosporine prevents seasonal recurrences of vernal keratoconjunctivitis in a randomized, double-masked, controlled 2-year study","volume":"128","author":"Lambiase","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib94","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1136\/bjo.79.5.482","article-title":"Collagen types I and III in giant papillae of vernal keratoconjunctivitis","volume":"79","author":"Leonardi","year":"1995","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib95","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/j.1398-9995.1995.tb01209.x","article-title":"Eosinophil cationic protein in tears of normal subjects and patients affected by vernal keratoconjunctivitis","volume":"50","author":"Leonardi","year":"1995","journal-title":"Allergy"},{"key":"10.1016\/j.survophthal.2023.10.008_bib96","first-page":"3036","article-title":"Identification of local Th2 and Th0 lymphocytes in vernal conjunctivitis by cytokine flow cytometry","volume":"40","author":"Leonardi","year":"1999","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"10.1016\/j.survophthal.2023.10.008_bib97","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1350-9462(02)00006-X","article-title":"Vernal keratoconjunctivitis: pathogenesis and treatment","volume":"21","author":"Leonardi","year":"2002","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.survophthal.2023.10.008_bib98","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1600-0420.2005.00622.x","article-title":"Case series of 406 vernal keratoconjunctivitis patients: a demographic and epidemiological study","volume":"84","author":"Leonardi","year":"2006","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1016\/j.survophthal.2023.10.008_bib99","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1007\/s00417-006-0285-7","article-title":"Th1- and Th2-type cytokines in chronic ocular allergy","volume":"244","author":"Leonardi","year":"2006","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib100","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1136\/bjo.2007.117515","article-title":"Clinical and biological efficacy of preservative-free NAAGA eye-drops versus levocabastine eye-drops in vernal keratoconjunctivitis patients","volume":"91","author":"Leonardi","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib101","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s40123-013-0019-y","article-title":"Management of vernal keratoconjunctivitis","volume":"2","author":"Leonardi","year":"2013","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.survophthal.2023.10.008_bib102","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.ajo.2012.11.018","article-title":"Vernal keratoconjunctivitis-like disease in adults","volume":"155","author":"Leonardi","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib103","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1111\/all.13178","article-title":"Diagnostic tools in ocular allergy","volume":"72","author":"Leonardi","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.survophthal.2023.10.008_bib104","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1136\/bjophthalmol-2017-311171","article-title":"Corneal staining patterns in vernal keratoconjunctivitis: the new VKC-CLEK scoring scale","volume":"102","author":"Leonardi","year":"2018","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib105","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ophtha.2018.12.027","article-title":"A randomized, controlled trial of cyclosporine A cationic emulsion in pediatric vernal keratoconjunctivitis: the VEKTIS study","volume":"126","author":"Leonardi","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2023.10.008_bib106","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1111\/all.13786","article-title":"Management of ocular allergy","volume":"74","author":"Leonardi","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.survophthal.2023.10.008_bib107","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1038\/s41433-022-02342-6","article-title":"Topical cyclosporine A cationic ophthalmic emulsion in paediatric vernal keratoconjunctivitis: pooled analysis of randomised NOVATIVE and VEKTIS trials","author":"Leonardi","year":"2023","journal-title":"Eye"},{"key":"10.1016\/j.survophthal.2023.10.008_bib108","doi-asserted-by":"crossref","first-page":"AB185","DOI":"10.1016\/j.jaci.2019.12.323","article-title":"Phase 1b study of AK002, an anti-Siglec-8 monoclonal antibody, in patients with severe allergic conjunctivitis (KRONOS study)","volume":"145","author":"Levine","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib109","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/ICO.0b013e3181eae270","article-title":"Subcutaneous allergen-specific immunotherapy versus topical treatment in vernal keratoconjunctivitis","volume":"31","author":"Mahdy","year":"2012","journal-title":"Cornea"},{"key":"10.1016\/j.survophthal.2023.10.008_bib110","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1136\/bjo.2007.122044","article-title":"Systematic review and meta-analysis of randomised clinical trials on topical treatments for vernal keratoconjunctivitis","volume":"91","author":"Mantelli","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib111","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/iid3.384","article-title":"Clinical efficacy and safety of omalizumab in conventional treatment-resistant vernal keratoconjunctivitis: our experience and literature review","volume":"9","author":"Manti","year":"2021","journal-title":"Immun Inflamm Dis"},{"key":"10.1016\/j.survophthal.2023.10.008_bib112","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3109\/08820538.2015.1123737","article-title":"Impact of vernal keratoconjunctivitis on school children in Egypt","volume":"32","author":"Marey","year":"2017","journal-title":"Semin Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib113","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s40265-016-0583-2","article-title":"Reslizumab: first global approval","volume":"76","author":"Markham","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.survophthal.2023.10.008_bib114","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s40123-019-0191-9","article-title":"Ocular surface diseases induced by dupilumab in severe atopic dermatitis","volume":"8","author":"Maudinet","year":"2019","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.survophthal.2023.10.008_bib115","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s12325-014-0155-3","article-title":"Ocular itch relief with alcaftadine 0.25% versus olopatadine 0.2% in allergic conjunctivitis: pooled analysis of two multicenter randomized clinical trials","volume":"31","author":"McLaurin","year":"2014","journal-title":"Adv Ther"},{"key":"10.1016\/j.survophthal.2023.10.008_bib116","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1097\/ICO.0000000000001963","article-title":"Safety and efficacy of supratarsal triamcinolone for treatment of vernal keratoconjunctivitis in Ireland","volume":"38","author":"McSwiney","year":"2019","journal-title":"Cornea"},{"key":"10.1016\/j.survophthal.2023.10.008_bib117","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.882240","article-title":"Diagnosis, management, and treatment of vernal keratoconjunctivitis in Asia: recommendations from the management of vernal keratoconjunctivitis in Asia Expert Working Group","volume":"9","author":"Mehta","year":"2022","journal-title":"Front Med"},{"key":"10.1016\/j.survophthal.2023.10.008_bib118","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.alit.2020.06.004","article-title":"Epidemiological aspects of allergic conjunctivitis","volume":"69","author":"Miyazaki","year":"2020","journal-title":"Allergol Int"},{"key":"10.1016\/j.survophthal.2023.10.008_bib119","doi-asserted-by":"crossref","first-page":"154","DOI":"10.5935\/0004-2749.20170038","article-title":"Tacrolimus eye drops as monotherapy for vernal keratoconjunctivitis: a randomized controlled trial","volume":"80","author":"M\u00fcller","year":"2017","journal-title":"Arq Bras Oftalmol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib120","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/ICL.0000000000000001","article-title":"Topical tacrolimus 0.03% as sole therapy in vernal keratoconjunctivitis: a randomized double-masked study","volume":"40","author":"M\u00fcller","year":"2014","journal-title":"Eye Contact Lens"},{"key":"10.1016\/j.survophthal.2023.10.008_bib121","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/BF01664932","article-title":"Levels of prostaglandin E2 and leukotriene B4 in tears of vernal conjunctivitis patients during a therapeutic trial with indomethacin","volume":"85","author":"Nathan","year":"1994","journal-title":"Doc Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib122","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3109\/08820538.2013.874483","article-title":"Pathogenesis of vernal keratoconjunctivitis and associated factors","volume":"30","author":"Nebbioso","year":"2015","journal-title":"Semin Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib123","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ajem.2014.09.036","article-title":"A randomized trial of benralizumab, an antiinterleukin 5 receptor \u03b1 monoclonal antibody, after acute asthma","volume":"33","author":"Nowak","year":"2015","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.survophthal.2023.10.008_bib124","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/pai.12350","article-title":"Vernal keratoconjunctivitis and immune-mediated diseases: one unique way to symptom control?","volume":"26","author":"Occasi","year":"2015","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib125","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/pai.12737","article-title":"Vernal keratoconjunctivitis treated with omalizumab: a case series","volume":"28","author":"Occasi","year":"2017","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib126","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s10384-012-0152-5","article-title":"Topical loteprednol etabonate 0.5 % for treatment of vernal keratoconjunctivitis: efficacy and safety","volume":"56","author":"Oner","year":"2012","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib127","first-page":"77","article-title":"Comparison of effects of alcaftadine and olopatadine on conjunctival epithelium and eosinophil recruitment in a murine model of allergic conjunctivitis","volume":"5","author":"Ono","year":"2011","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.survophthal.2023.10.008_bib128","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/ACI.0b013e328364d86a","article-title":"Immunomodulators for conjunctivitis","volume":"13","author":"Pacharn","year":"2013","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib129","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2147\/PROM.S146966","article-title":"Impact of reslizumab on outcomes of severe asthmatic patients: current perspectives","volume":"9","author":"Padilla Galo","year":"2018","journal-title":"Patient Relat Outcome Meas"},{"key":"10.1016\/j.survophthal.2023.10.008_bib130","doi-asserted-by":"crossref","first-page":"4187","DOI":"10.2147\/OPTH.S279051","article-title":"A review of the mechanism of action of cyclosporine A: the role of cyclosporine A in dry eye disease and recent formulation developments","volume":"14","author":"Periman","year":"2020","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib131","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1038\/s41433-020-01379-9","article-title":"Dupilumab-associated ocular surface disease: presentation, management and long-term sequelae","volume":"35","author":"Popiela","year":"2021","journal-title":"Eye"},{"key":"10.1016\/j.survophthal.2023.10.008_bib132","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1081-1206(10)61958-8","article-title":"Efficacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis","volume":"89","author":"Pucci","year":"2002","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib133","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1046\/j.1365-2222.2003.01538.x","article-title":"Atopy and serum eosinophil cationic protein in 110 white children with vernal keratoconjunctivitis: differences between tarsal and limbal forms","volume":"33","author":"Pucci","year":"2003","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.survophthal.2023.10.008_bib134","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1177\/039463201002300322","article-title":"Long-term safety and efficacy of topical cyclosporine in 156 children with vernal keratoconjunctivitis","volume":"23","author":"Pucci","year":"2010","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib135","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/pai.12360","article-title":"Tacrolimus vs. cyclosporine eyedrops in severe cyclosporine-resistant vernal keratoconjunctivitis: a randomized, comparative, double-blind, crossover study","volume":"26","author":"Pucci","year":"2015","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib136","first-page":"34","article-title":"Comparative efficacy of medical treatments for vernal keratoconjunctivitis in children and young adults: a systematic review with network meta-analyses","author":"Rasmussen","year":"2021","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib137","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2018.00049","article-title":"Targeting the interleukin-5 pathway for treatment of eosinophilic conditions other than asthma","volume":"5","author":"Roufosse","year":"2018","journal-title":"Front Med"},{"key":"10.1016\/j.survophthal.2023.10.008_bib138","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.jaci.2021.03.026","article-title":"Efficacy of medical treatments for vernal keratoconjunctivitis: a systematic review and meta-analysis","volume":"148","author":"Roumeau","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib139","doi-asserted-by":"crossref","first-page":"486","DOI":"10.4103\/0301-4738.119431","article-title":"Demographic and clinical profile of vernal keratoconjunctivitis at a tertiary eye care center in India","volume":"61","author":"Saboo","year":"2013","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib140","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.ajo.2007.06.028","article-title":"Development and testing of the quality of life in children with vernal keratoconjunctivitis questionnaire","volume":"144","author":"Sacchetti","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib141","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.ophtha.2009.11.043","article-title":"Tailored approach to the treatment of vernal keratoconjunctivitis","volume":"117","author":"Sacchetti","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2023.10.008_bib142","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1080\/21678707.2017.1300524","article-title":"Current and emerging treatment options for vernal keratoconjunctivitis","volume":"5","author":"Sacchetti","year":"2017","journal-title":"Expert Opin Orphan Drugs"},{"issue":"10","key":"10.1016\/j.survophthal.2023.10.008_bib143","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.3390\/life11101012","article-title":"Understanding vernal keratoconjunctivitis: beyond allergic mechanisms","volume":"11","author":"Sacchetti","year":"2021","journal-title":"Life"},{"key":"10.1016\/j.survophthal.2023.10.008_bib144","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1034\/j.1600-0420.1999.770505.x","article-title":"Efficacy of supratarsal dexamethasone versus triamcinolone injection in recalcitrant vernal keratoconjunctivitis","volume":"77","author":"Saini","year":"1999","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1016\/j.survophthal.2023.10.008_bib145","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaapos.2018.09.010","article-title":"Monotherapy of topical tacrolimus 0.03% in the treatment of vernal keratoconjunctivitis in the pediatric population","volume":"23","author":"Samyukta","year":"2019","journal-title":"J AAPOS"},{"key":"10.1016\/j.survophthal.2023.10.008_bib146","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/BF02877768","article-title":"Perception and quality of life associated with the use of olopatadine 0.2% (Pataday) in patients with active allergic conjunctivitis","volume":"24","author":"Scoper","year":"2007","journal-title":"Adv Ther"},{"key":"10.1016\/j.survophthal.2023.10.008_bib147","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3109\/09273949509057807","article-title":"The role of eosinophil cationic protein (ECP) and histamine in vernal keratoconjunctivitis","volume":"3","author":"Secchi","year":"1995","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.survophthal.2023.10.008_bib148","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0002-9394(14)77061-8","article-title":"Topical use of cyclosporine in the treatment of vernal keratoconjunctivitis","volume":"110","author":"Secchi","year":"1990","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib149","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.4103\/ijo.IJO_2143_18","article-title":"Pattern of steroid misuse in vernal keratoconjunctivitis resulting in steroid induced glaucoma and visual disability in Indian rural population: an important public health problem in pediatric age group","volume":"67","author":"Sen","year":"2019","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib150","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/bjophthalmol-2019-313988","article-title":"Steroid-induced glaucoma and blindness in vernal keratoconjunctivitis","volume":"104","author":"Senthil","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib151","first-page":"177","article-title":"Topical ketorolac 0.5% solution for the treatment of vernal keratoconjunctivitis","volume":"45","author":"Sharma","year":"1997","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib152","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2147\/OPTH.S99157","article-title":"Efficacy and safety of low-dose topical tacrolimus in vernal keratoconjunctivitis","volume":"10","author":"Shoughy","year":"2016","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib153","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/sj.eye.6702474","article-title":"Prospective, long-term evaluation of steroid-induced glaucoma","volume":"22","author":"Sihota","year":"2008","journal-title":"Eye"},{"key":"10.1016\/j.survophthal.2023.10.008_bib154","first-page":"241","article-title":"Supratarsal injection of corticosteroids in the treatment of refractory vernal keratoconjunctivitis","volume":"49","author":"Singh","year":"2001","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib155","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.survophthal.2018.12.001","article-title":"Vernal keratoconjunctivitis","volume":"64","author":"Singhal","year":"2019","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib156","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1399-3038.2006.00427.x","article-title":"Efficacy of 1.25% and 1% topical cyclosporine in the treatment of severe vernal keratoconjunctivitis in childhood","volume":"17","author":"Spadavecchia","year":"2006","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib157","doi-asserted-by":"crossref","first-page":"476","DOI":"10.4103\/ijp.IJP_174_20","article-title":"To evaluate the efficacy and safety of olopatadine 0.1% ophthalmic solution and bepotastine 1.5% ophthalmic solution in patients with vernal keratoconjunctivitis in a tertiary care hospital","volume":"52","author":"Sruthi","year":"2020","journal-title":"Indian J Pharmacol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib158","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.jaci.2008.02.033","article-title":"Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels","volume":"121","author":"Stein","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib159","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/09286580701299411","article-title":"Topical non-steroidal anti-inflammatory drugs in allergic conjunctivitis: meta-analysis of randomized trial data","volume":"14","author":"Swamy","year":"2007","journal-title":"Ophthalmic Epidemiol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib160","first-page":"88","article-title":"Ocular complications of vernal keratoconjunctivitis","volume":"34","author":"Tabbara","year":"1999","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib161","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1001\/archopht.119.3.338","article-title":"Tear tryptase in vernal keratoconjunctivitis","volume":"119","author":"Tabbara","year":"2001","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib162","article-title":"Treatment of asymmetrical vernal keratoconjunctivitis with supratarsal corticosteroid injection","volume":"2014","author":"Thanathanee","year":"2014","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.survophthal.2023.10.008_bib163","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000234508","article-title":"Inhibition by nedocromil sodium of IgE-mediated activation of human mononuclear phagocytes and platelets in allergy","volume":"85","author":"Thorel","year":"1988","journal-title":"Int Arch Allergy Appl Immunol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib164","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1076\/ceyr.26.5.319.15437","article-title":"Neutrophil and eosinophil participation in atopic and vernal keratoconjunctivitis","volume":"26","author":"Trocme","year":"2003","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.survophthal.2023.10.008_bib165","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1111\/ceo.14142","article-title":"Successful treatment and prevention of the recurrence of refractory vernal keratoconjunctivitis with dupilumab","volume":"50","author":"Tsui","year":"2022","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib166","doi-asserted-by":"crossref","first-page":"525","DOI":"10.2147\/OPTH.S3294","article-title":"Treatment of allergic conjunctivitis with olopatadine hydrochloride eye drops","volume":"2","author":"Uchio","year":"2008","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib167","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1089\/jop.2012.0054","article-title":"Rebamipide suppresses PolyI:C-stimulated cytokine production in human conjunctival epithelial cells","volume":"29","author":"Ueta","year":"2013","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.survophthal.2023.10.008_bib168","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2332\/allergolint.13-OA-0605","article-title":"Usefulness of a new therapy using rebamipide eyedrops in patients with VKC\/AKC refractory to conventional anti-allergic treatments","volume":"63","author":"Ueta","year":"2014","journal-title":"Allergol Int"},{"key":"10.1016\/j.survophthal.2023.10.008_bib169","doi-asserted-by":"crossref","first-page":"P94","DOI":"10.1016\/j.ophtha.2018.10.020","article-title":"Conjunctivitis preferred practice pattern","volume":"126","author":"Varu","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2023.10.008_bib170","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1177\/112067210101100203","article-title":"Comparison of lodoxamide 0.1% ophthalmic solution and levocabastine 0.05% ophthalmic suspension in vernal keratoconjunctivitis","volume":"11","author":"Verin","year":"2001","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib171","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1046\/j.1365-2222.1999.00501.x","article-title":"Nedocromil sodium eye drops are more effective than sodium cromoglycate eye drops for the long-term management of vernal keratoconjunctivitis","volume":"29","author":"Verin","year":"1999","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.survophthal.2023.10.008_bib172","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/pai.12197","article-title":"Vernal keratoconjunctivitis: a severe allergic eye disease with remodeling changes","volume":"25","author":"Vichyanond","year":"2014","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib173","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1159\/000478704","article-title":"Therapeutic effect of 0.1% tacrolimus eye drops in the tarsal form of vernal keratoconjunctivitis","volume":"59","author":"Wan","year":"2018","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.survophthal.2023.10.008_bib174","first-page":"137","article-title":"Characterization of receptor subtypes involved in prostanoid-induced conjunctival pruritus and their role in mediating allergic conjunctival itching","volume":"279","author":"Woodward","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.survophthal.2023.10.008_bib175","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ajo.2022.03.026","article-title":"Risk of elevated intraocular pressure with difluprednate in patients with non-infectious uveitis","volume":"240","author":"Yakin","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib176","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/archopht.117.5.643","article-title":"Inhibition of histamine-induced human conjunctival epithelial cell responses by ocular allergy drugs","volume":"117","author":"Yanni","year":"1999","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib177","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000501637","article-title":"AK002, a humanized sialic acid-binding immunoglobulin-like lectin-8 antibody that induces antibody-dependent cell-mediated cytotoxicity against human eosinophils and inhibits mast cell-mediated anaphylaxis in mice","volume":"180","author":"Youngblood","year":"2019","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib178","doi-asserted-by":"crossref","first-page":"507","DOI":"10.11622\/smedj.2015161","article-title":"Efficacy and safety of topical cyclosporine A 0.05% in vernal keratoconjunctivitis","volume":"57","author":"Y\u00fccel","year":"2016","journal-title":"Singapore Med J"},{"key":"10.1016\/j.survophthal.2023.10.008_bib179","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/ICO.0000000000001200","article-title":"Comparative evaluation of tacrolimus versus interferon alpha-2b eye drops in the treatment of vernal keratoconjunctivitis: a randomized, double-masked study","volume":"36","author":"Zanjani","year":"2017","journal-title":"Cornea"},{"key":"10.1016\/j.survophthal.2023.10.008_bib180","first-page":"604","article-title":"Successful treatment of severe recalcitrant vernal keratoconjunctivitis and atopic dermatitis associated with elevated IgE levels with omalizumab","author":"Zengarini","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib181","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1001\/jamaophthalmol.2021.1708","article-title":"Association of allergic conjunctivitis with health-related quality of life in children and their parents","volume":"139","author":"Zhang","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.10.008_bib182","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1136\/ejhpharm-2020-002447","article-title":"Therapeutic efficacy of tacrolimus in vernal keratoconjunctivitis: a meta-analysis of randomised controlled trials","volume":"29","author":"Zhao","year":"2022","journal-title":"Eur J Hosp Pharm"},{"key":"10.1016\/j.survophthal.2023.10.008_bib183","doi-asserted-by":"crossref","DOI":"10.1186\/s13052-019-0656-4","article-title":"Vernal keratoconjunctivitis: an update focused on clinical grading system","volume":"45","author":"Zicari","year":"2019","journal-title":"Ital J Pediatr"},{"key":"10.1016\/j.survophthal.2023.10.008_bib184","unstructured":"US Food and Drug Administration, Center for Drug Evaluation and Research. Approval package for olopatadine hydrochloride. February 14, 2020. Available at \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2022\/021545Orig1s022.pdf\u3009. Accessed 06 September 2023."},{"key":"10.1016\/j.survophthal.2023.10.008_bib185","unstructured":"European Medicines Agency. Assessment Report for Paediatric Studies Submitted According to Article 46 of the Regulation (EC) No. 1901\/2006 for Opatanol (olopatadine). December 13, 2018. Available at \u3008https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/opatanol-h-c-407-p46\u2013027-epar-assessment-report_en.pdf\u3009. Accessed 06 September 2023."},{"key":"10.1016\/j.survophthal.2023.10.008_bib186","unstructured":"Health Canada. Product Monograph, Including Patient Medication Information: Verkazia\u2122 Cyclosporine Topical Ophthalmic Emulsion, 0.1%. Ottawa, Ontario, Canada, 2018. Available at \u3008https:\/\/pdf.hres.ca\/dpd_pm\/00048991.PDF\u3009. Accessed 06 September 2023."},{"key":"10.1016\/j.survophthal.2023.10.008_bib187","unstructured":"US Food and Drug Administration. Full prescribing information: Verkazia\u00ae (cyclosporine ophthalmic emulsion) 0.1%. Silver Spring, Maryland, 2021. Available at \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/214965s000lbl.pdf\u3009. Accessed 06 September 2023."},{"key":"10.1016\/j.survophthal.2023.10.008_bib188","unstructured":"European Medicines Agency. Assessment Report: Verkazia. London, UK, 2017. Available at \u3008https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/verkazia-epar-public-assessment-report_en.pdf\u3009. Accessed 06 September 2023."},{"key":"10.1016\/j.survophthal.2023.10.008_bib189","unstructured":"Health Canada. Product Monograph, Including Patient Medication Information: Protopic\u00ae Tacrolimus Ointment 0.03% and 0.1% (w\/w) Topical Calcineurin Inhibitor. Ottawa, Ontario, Canada, 2021. Available at \u3008https:\/\/www.leo-pharma.ca\/Files\/Filer\/Protopic_PM_Aug2021_EN.pdf\u3009. Accessed 06 September 2023."},{"key":"10.1016\/j.survophthal.2023.10.008_bib190","unstructured":"Evaluation of Dupilumab in Patients With Atopic Keratoconjunctivitis (AKC). NCT04296864. Clinical Trials.gov. Posted March 09, 2023. Available at \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT04296864\u3009. Accessed 06 September 2023."}],"container-title":["Survey of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625723001388?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625723001388?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T21:11:35Z","timestamp":1737839495000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039625723001388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":190,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0039625723001388"],"URL":"https:\/\/doi.org\/10.1016\/j.survophthal.2023.10.008","relation":{},"ISSN":["0039-6257"],"issn-type":[{"value":"0039-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of vernal keratoconjunctivitis: Navigating a changing treatment landscape","name":"articletitle","label":"Article Title"},{"value":"Survey of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.survophthal.2023.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}